Late results of treatment of patients, suffering ischemic cardiomyopathy, with application of stem cells of umbilical blood
Objective. Comparative analysis of late results of the stem cells transplantation, obtained from umbilical blood (SCTUB) and surgical revascularization in patients, suffering an ischemic cardiomyopathy (ІCMP).
Маterials and methods. Late results of teatment in 113 patients, suffering chronic cardiac insufficiency on background of ІCMP, were analyzed. In 38 (33.6%) patients the isolated coronary shunting was performed, in 35 (31.0%) – stenting of coronary arteries, in 20 (17.7%) – surgical revascularization was added by SCTUB. Separate group of the patients, consisted of 20 (17.7%) persons, in whom independent conservative therapy was accomplished. The follow–up duration have constituted 12 mo.
Results. In 6 mo after SCTUB in the patients, suffering ІCMP the left ventricular ejection fraction have raised from 24.8 tо 33.3% (р < 0.05), while the level of N–terminal pro brain natriuretic peptidе (proBNP) have lowered by 51.6% (from 499.0 tо 257.5 pg/ ml). The effect achieved have persisted through 12 mo of observation. Holter day monitoring of electrocardiogram, conducted in 3, 6 and 12 mo after SCTUB, did not show trustworthy enhancement of risk for occurrence of fatal arrhythmia.
Conclusion. Application of SCTUB in complex of treatment in patients, suffering ІCMP, favorably impacts prognosis for the cardio–vascular mortality, reduces the cardiac insufficiency signs, improves the patients’ quality of life and myocardium’s contractile function trustworthily.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jule; 37(27):2129-200. https://doi.org/10.1093/eurheartj/ehw128.
3. Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clin Med Insights Cardiol. 2018 Jan 8;12:1179-89. https://doi.org/10.1177/1179546817751609.
4. Papa AA, D’Ambrosio P, Petillo R, Palladino A, Politano L. Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series. Intractable Rare Dis Res. 2017;6(2):95-101. https://doi.org/10.5582/irdr.2017.01024.
5. Lund LH. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report - 2013; Focus Theme: Age J. Heart Lung Transplant. 2013 Oct;32 (10):951-64. https://doi.org/10.1016/j.healun.2013.08.006.
6. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 2013 Aug 30;113 (6):810-34. https://doi.org/10.1161/CIRCRESAHA.113.300219.
7. Mathur A, Arnold R, Assmus B, Bartunek J, Belmans A, Bonig H, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial. Eur J Heart Fail. 2017 Nov;19(11):1545-50. https://doi.org/10.1002/ejhf.829.
8. Velazquez E, Lee K, Jones R, Al-Khalidi H, Hill JA, Panza JA, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016 Apr 21;374(16):1511-20. https://doi.org/10.1056/NEJMoa1602001.
9. Zharinov OI, Pinchuk AV, Shnyrkova YeV, Kuts VA, Sohrab K, et al. Surgical treatment of the ischemic cardiomyopathy. Role of the myocardial viability. Kardiokhirurhiia ta interventsiina kardiolohiia. 2013;(1);51-7. [In Russian].
10. Murashita T. The role of coronary artery bypass grafting in patients with ischemic cardiomyopathy in the current era. J Thorac Dis 2016 Sep;8(9):E1032-E1033. https://doi.org/10.21037/jtd.2016.08.37.
This work is licensed under a Creative Commons Attribution 4.0 International License.